A meta-analysis of 27 randomized controlled trials with nearly 200,000 patients found that GLP-1 receptor agonists, particularly semaglutide, reduced the risk of late-onset seizures and epilepsy by 24% compared to placebo.
24% seizure/epilepsy risk reductionGLP-1 receptor agonists vs placebo in meta-analysis of 27 RCTs with ~200,000 patients
What the researchers found
GLP-1 receptor agonists reduced the risk of late-onset seizures and epilepsy by 24% (RR: 0.76, 95% CI: 0.62-0.95) in a meta-analysis of 27 RCTs with ~200,000 patients. The benefit was specific to GLP-1 RAs, not DPP-4i or SGLT2i.
Why it matters
Late-onset epilepsy is a growing concern in aging populations. Finding that widely prescribed GLP-1 drugs also protect against seizures could be clinically significant for millions of diabetic patients, and raises the possibility of repurposing these drugs for epilepsy prevention in high-risk groups.
The numbers in context
The analysis included data from RCTs of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors across multiple databases (MEDLINE and CENTRAL).
How the study worked
Meta-analysis of 27 randomized controlled trials from MEDLINE and CENTRAL databases comparing newer glucose-lowering drugs (DPP-4i, GLP-1 RAs, SGLT2i) to placebo. Assessed seizure and epilepsy as adverse events. Calculated RR using Mantel-Haenszel method and OR using Peto's method. Mean age 64.9 years, 65.6% male.
Who was studied
Adults with type 2 diabetes in cardiovascular and renal outcome trials
What this study cannot tell us
Seizures and epilepsy were captured as adverse events in cardiovascular/renal outcome trials, not as primary endpoints — potentially underreported. The mechanism (anti-inflammatory, neuroprotective, or other) is not established. The patient population was primarily older adults with type 2 diabetes — generalizability to non-diabetic populations is unknown.
How to read the evidence
Moderate to strong evidence from a meta-analysis of randomized controlled trials. However, seizure/epilepsy was a secondary/adverse event outcome, not a primary endpoint, which limits the confidence of the finding.
When this study was published
Published in 2024. First meta-analysis to examine GLP-1RA effects on seizure and epilepsy risk.
The bigger picture
This adds epilepsy prevention to the growing list of non-metabolic benefits attributed to GLP-1 receptor agonists, alongside cardiovascular protection, neuroprotection, and potential kidney benefits. The anti-epileptogenic effect appears independent of stroke reduction, suggesting a direct neuroprotective mechanism.
Questions still open
- Would GLP-1 drugs prevent seizures in non-diabetic populations at risk for late-onset epilepsy?
- What is the mechanism by which GLP-1 receptor agonists reduce seizure risk?
- Should GLP-1RA use be considered as a factor when evaluating seizure risk in diabetic patients?
Common questions
Why might GLP-1 drugs prevent seizures?
Should diabetic patients switch to GLP-1 drugs to prevent seizures?
Read the original research
Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.
Epilepsia open, 9(6), 2528-2536
Citation
Sindhu, Udeept; Sharma, Akshay; Zawar, Ifrah; Punia, Vineet. (2024). Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.. Epilepsia open, 9(6), 2528-2536. https://doi.org/10.1002/epi4.13091